BioVie Closes Registered Direct Offering and Concurrent Private Placement

October 23, 2024

DENVER, Colo., Oct 23, 2024 (247marketnews.com)- BioVie (NASDAQ: BIVI) stated that the Company closed its previously announced registered direct offering of 4,443,000 common stock shares at-the-market price of $1.50 per share and a concurrent private placement.

Additionally, BioVie issued and sold unregistered warrants to purchase up to 4,443,000 shares of its common stock, with each warrant exercisable for one share of common stock at an exercise price of $1.37 per share. The offering’s gross proceeds to the Company from the offering are $6,664,500, less fees and expenses, for working capital and general corporate purposes. The warrant exercise windows will start in six months and expire five years.

BioVie started squuezing a few days after it announced that it received a Notice of Allowance from the Japan Patent Office for patent application no. 2021-569344 entitled “Formulations of Terlipressin. MoBot alerted the move at $1.27.

Please go to 247marketnews.com to sign up for free MoBot alerts and view Mobot’s real time data.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (BIVI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.